The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with elevated eosinophil levels. Clinical trials show that Dupixent reduces ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Dupixent is a prescription drug that can be used to treat chronic rhinosinusitis due to nasal polyps. Learn more about side effects, dosage, and how it works for this condition.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products Administration in China has approved Dupixent ® as an add-on maintenance treatment for adults with ...

Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic ...

In pooled data from all three trials, the most common adverse event (≥2%) more frequently observed in patients on Dupixent compared to placebo was injection site reactions.

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in ...

“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over 10 years, with pivotal trials demonstrating its ability to help patients significantly reduce the ...

DUPIXENT® has since been approved for the treatment of adolescents, children and infants aged 6 months and older with moderate-to-severe atopic dermatitis; adults with chronic rhinosinusitis with ...